INTRODUCING THEROMICS INC.
We make soft tissue ablation more effective
We augment and optimize thermal ablation
Theromics is developing a next-generation thermal accelerant technology for soft tissue ablation procedures and combination therapy. The Company's proprietary HeatSYNC™ gel is based on a protein naturally found in the body and may increase cost-efficiencies and improve outcomes through more focused and patient-centric delivery. The Company will first focus on tumor ablations and then expand into additional applications, including pain and abnormal uterine bleeding. Longer-term, Theromics plans to apply its thermal technology for use as an oncolytic intratumoral drug/immunotherapy delivery platform with the potential to enhance efficacy and improve safety profiles of currently approved medicines. For more information, visit www.theromicsinc.com.
HeatSYNC TA Thermal Accelerant
Theromics Inc. has developed HeatSYNC™ Gel, a novel thermal accelerant (TA) that is able to augment MW and RF energy by increasing local tissue electrical conductivity in a reproducible and effective manner. Our efforts to develop a novel TA to augment MW and RF energy enabled us to develop a material with high dipole moment, to optimize probe and antennae energy. Our gel is placed next to or into the lesion undergoing treatment via a percutaneous needle stick, a familiar approach to all clinicians. It does not migrate and is integrated into the lesion post-procedure before being absorbed by the body.
Caution: This device is for Investigational Use Only and has not been cleared by the FDA or other regulatory bodies.